China has authorized Orzeyful, a novel treatment for narcolepsy type 1, making it the first country to do so. The approval is based on two international trials and targets patients from age 16. The drug offers a new approach by restoring orexin signaling, setting it apart from existing therapies.
On July 22, China became the first country to approve Orzeyful, a new medication for narcolepsy type 1, for patients aged 16 and older. The decision, announced by the National Medical Products Administration, marks a significant step in the treatment of this chronic neurological disorder, which is characterized by excessive daytime sleepiness and sudden loss of muscle tone known as cataplexy.
Orzeyful, also known as oveporexton, is an oral selective agonist of the orexin receptor 2 (OX2R). Unlike current therapies that mainly address individual symptoms, this drug aims to restore the disrupted orexin signaling in the brain—a core issue in narcolepsy type 1. Orexin is a neuropeptide that stabilizes the sleep-wake cycle, and its deficiency leads to the hallmark symptoms of the disease.
How Orzeyful Works
Narcolepsy type 1 is caused by the loss of neurons that produce orexin, resulting in persistent drowsiness, cataplexy, fragmented nighttime sleep, sleep paralysis, hallucinations, and attention difficulties. Orzeyful does not replace lost neurons or offer a cure, but it selectively stimulates the OX2R receptor to help restore orexin signaling and promote wakefulness. The drug also targets REM sleep-related symptoms, including cataplexy. The current approval in China is limited to patients aged 16 and above with narcolepsy type 1, excluding younger patients and those with other hypersomnia disorders.
Clinical Trials and Results
The approval is based on two phase 3 studies—FirstLight and RadiantLight—conducted over 12 weeks in 19 countries with a total of 273 participants. FirstLight enrolled 168 patients and compared two daily doses of Orzeyful to placebo, while RadiantLight included 105 patients and tested a two-milligram twice-daily regimen. Both studies met their primary and secondary endpoints, evaluating wakefulness, sleepiness, cataplexy, attention, and quality of life.
According to Takeda, the manufacturer, nearly 85% of treated participants achieved levels of sleepiness similar to healthy individuals. The median reduction in weekly cataplexy episodes exceeded 80%, with patients gaining four to five cataplexy-free days per week compared to none at baseline. No serious treatment-related adverse events were reported; the most common side effects were insomnia, urinary urgency, and increased urination. Over 95% of those who completed the trials entered an extension study.
Scope and Limitations
Official estimates suggest around 700,000 people in China live with some form of narcolepsy, but only 75–80% have type 1, translating to roughly 525,000–560,000 potential candidates. However, the age restriction to 16 and older means not all patients are immediately eligible. Narcolepsy often begins between ages 10 and 20, and diagnosis can be delayed for years, affecting education, employment, driving, and social life. The condition is also linked to higher risks of accidents, anxiety, and depression. In Spain, for example, eligibility for permanent disability benefits depends on functional limitations rather than diagnosis alone, and the new approval does not guarantee immediate return to normal work activity for all patients.
International Status and Next Steps
While China has moved forward, Orzeyful remains under review in other major markets. The United States is conducting a priority review, with a decision expected in the third quarter of 2026. Japan is also evaluating the drug through its accelerated Sakigake process. As of late July, both regulatory processes were ongoing. The clinical trials compared Orzeyful to placebo, not directly to all existing treatments.
The number of patients who will start treatment immediately in China is still unclear. Takeda plans to launch the drug in the country in the second half of 2026, but details on pricing, reimbursement, and exact availability have not been disclosed. The timeline for potential approval in Spain and other countries will depend on future regulatory submissions and decisions.
For now, Orzeyful represents a notable advance in narcolepsy treatment, but its impact will depend on broader access and further regulatory outcomes. As the landscape evolves, patients and clinicians will be watching closely for updates from other markets.
